Cite
MLA Citation
E. Shinozaki et al.. “2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC).” European journal of cancer, vol. 51, n.d., pp. S383–S384. http://access.bl.uk/ark:/81055/vdc_100030628213.0x000033